Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1008457

	registered interest
	date	16/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Statins
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the supply of statins after the UK leaves the EU.
	tabling member constituency	Tooting
	tabling member printed	Dr Rosena Allin-Khan
	uin	192116
	answer	answer is ministerial correction date of answer 22/11/2018 answer text <p>Until we can be certain of the outcome of Brexit negotiations our duty as a responsible government is to prepare for all eventualities, including ‘no deal’. On 23 August 2018, therefore, the Department wrote to all pharmaceutical companies that supply the United Kingdom with prescription only or pharmacy medicines from, or via, the European Union/European Economic Area, asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no-deal scenario.</p><p> </p><p>Since then, we have received very good engagement from industry who share our aims of ensuring continuity of medicines supply for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal Brexit.</p><p> </p><p>We understand that statins are vitally important to many people in this country. However, the Department recognises that through its medicines supply contingency programme it is requesting sensitive commercial information from pharmaceutical companies. To reassure participating companies, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s programme. That means not introducing information about a company, specific medicine or their supply routes into the public domain.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/11/2018 15:21:08 answering member 4067 label Biography information for Steve Brine
	tabling member	4573 label Biography information for Dr Rosena Allin-Khan

1046805

	registered interest
	date	23/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Epilepsy: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to maintain the supply of medication for epilepsy after the UK leaves the EU.
	tabling member constituency	Tooting
	tabling member printed	Dr Rosena Allin-Khan
	uin	211841
	answer	answer is ministerial correction date of answer 31/01/2019 answer text <p>Our European Union exit medicines supply contingency plans aim to ensure that the supply of epilepsy medicines and other essential medicines is not disrupted in all EU exit scenarios.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 31/01/2019 17:28:19 answering member 1585 label Biography information for Stephen Hammond
	tabling member	4573 label Biography information for Dr Rosena Allin-Khan

1063766

	registered interest
	date	18/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Epilepsy: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 31 January 2019 to Question 211841, what specific steps his Department has taken to ensure the supply of epilepsy medication in the event of the UK leaving the EU without a deal.
	tabling member constituency	Tooting
	tabling member printed	Dr Rosena Allin-Khan
	uin	222701
	answer	answer is ministerial correction date of answer 26/02/2019 answer text <p>We understand that epilepsy medicines are vitally important to many people in this country. Our contingency plans aim to ensure that the supply of epilepsy medicines and other essential medicines to patients is not disrupted in all European Union exit scenarios, including in the event of a ‘no deal’ exit.</p><p> </p><p>In August 2018, the Department wrote to all pharmaceutical companies that supply prescription-only and pharmacy medicines to the United Kingdom that come from, or via, the EU/European Economic Area asking them to ensure a minimum of six weeks’ additional supply in the UK, over and above existing business-as-usual buffer stocks, by 29 March 2019.</p><p> </p><p>On 7 December, the Government published updated reasonable worst-case scenario border disruption planning assumptions in the event of a ‘no deal’ EU exit. Medicines and medical products are prioritised in cross-Government planning, and the Department is working with relevant partners across Government and industry to ensure we have sufficient roll-on, roll-off freight capacity on alternative routes to enable these vital products to continue to move freely into the UK.</p><p> </p><p>Throughout the implementation of our plans, we have received very good engagement from industry who share our aims of ensuring that the supply of medicines and medical products can continue unhindered in the event of a ‘no deal’ EU exit.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 26/02/2019 12:05:08 answering member 1585 label Biography information for Stephen Hammond
	tabling member	4573 label Biography information for Dr Rosena Allin-Khan

1092719

	registered interest
	date	21/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Alcoholism and Drugs: Rehabilitation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what proportion of NHS spending is allocated to drug and alcohol rehabilitation services.
	tabling member constituency	Tooting
	tabling member printed	Dr Rosena Allin-Khan
	uin	235390
	answer	answer is ministerial correction date of answer 29/03/2019 answer text <p>In the financial year 2017-18 the estimated total cost to National Health Service trusts and NHS foundation trusts for providing rehabilitation for drug and alcohol addiction is £572,000. The majority of drug and alcohol services fall under the remit of local authorities who are responsible for assessing local need and commissioning services to meet identified needs, including for drug and alcohol dependence, using the ringfenced public health grant.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 29/03/2019 14:38:57 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4573 label Biography information for Dr Rosena Allin-Khan

1105574

	registered interest
	date	27/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Urinary Tract Infections: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the gold-standard urinary tract infections test kit used by the NHS.
	tabling member constituency	Tooting
	tabling member printed	Dr Rosena Allin-Khan
	uin	237733
	answer	answer is ministerial correction date of answer 05/04/2019 answer text <p>The phrase global or gold standard test is sometimes used to refer to dipstick strip, which are available in home kits, and urine culture tests for urinary tract infection (UTI). The way in which laboratories determine if a UTI is present involves screening tests to look for human cells/blood/protein in the urine, which can be done by machines or using dipsticks, followed by culturing urine to determine if UTI pathogens are present and in sufficient numbers. This second stage process relies on bacterial media/culture techniques and is usually not a specific ‘kit’. If a pathogen is present then the third stage is to determine the antibiotic susceptibility profile of the bacteria.</p><p> </p><p>Guidance on identification and treatment of UTI has been published for different age groups and clinical settings. The National Institute for Health and Care Excellence have published guidance for under 16s at the following link:</p><p> </p><p><a href="https://www.nice.org.uk/guidance/cg54" target="_blank">https://www.nice.org.uk/guidance/cg54</a></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 05/04/2019 11:13:08 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4573 label Biography information for Dr Rosena Allin-Khan

1105597

	registered interest
	date	27/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dental Services: Fees and Charges
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the five per cent increase in patient charges for NHS dental treatment on the affordability of that treatment for patients.
	tabling member constituency	Tooting
	tabling member printed	Dr Rosena Allin-Khan
	uin	237747
	answer	answer is ministerial correction date of answer 04/04/2019 answer text <p>The Department has undertaken equality analysis and impact assessment setting out the potential impacts on patients, which can be accessed at the following link:</p><p> </p><p><a href="http://www.legislation.gov.uk/uksi/2019/522/made" target="_blank">http://www.legislation.gov.uk/uksi/2019/522/made</a></p><p> </p><p>There have been no changes to exemption arrangements. Those who qualify for free dental treatment will remain entirely exempt from charges, which includes those under the age of 18, those under the age of 19 and in full-time education, pregnant women and or those that have had a baby in the previous 12 months, and those on qualifying benefits will not be impacted by these changes.</p><p> </p><p>For those adults who do not qualify for exemption from dental charges, but who are on low incomes, are eligible to receive, full or partial help for health costs through the NHS Low Income Scheme.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 04/04/2019 12:36:36 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4573 label Biography information for Dr Rosena Allin-Khan

1109224

	registered interest
	date	02/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Integrated Care Systems
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what comparative assessment he has made of the effectiveness of (a) Integrated Care Organisations and (b) pre-existing NHS England arrangements; and what assessment he has made of the effect of those (a) organisations and (b) arrangements on patient care.
	tabling member constituency	Tooting
	tabling member printed	Dr Rosena Allin-Khan
	uin	240061
	answer	answer is ministerial correction date of answer 10/04/2019 answer text <p>Integrated Care Organisations’ is not a term currently used by NHS England, so the answer below refers to Integrated Care Providers.</p><p> </p><p>‘Integrated Care Provider’ (ICP) is a term used to describe a provider that is responsible for the integrated provision of general practice, wider National Health Service and potentially local authority services, which enters into an ICP contract with the commissioner(s) of those services. The ICP would be a ‘lead’ provider organisation, and so would be contractually responsible for delivering integrated services for local people. An ICP is not a new type of legal entity, but simply the name for a provider organisation awarded an ICP contract. The ICP contract is itself a variant of the generic NHS Standard Contract (which is already used to commission a broad range of NHS services) and has been specifically designed to enable integration through a single contract that could be used to commission both primary medical services and other health and care services.</p><p> </p><p>There are not yet any ICPs in place in England. However, NHS England plans to study the effects of the first ICP contracts that come into being and share learning with others that may follow. Where a clinical commissioning group (CCG) proposes to use the ICP contract in future, proposals will be subject to successful completion of the Integrated Support and Assurance Process, managed by NHS England and NHS Improvement, before the ICP Contract is awarded.</p><p> </p><p>Further information about ICPs is available in NHS England’s package of consultation materials and response to consultation, which are available at the following link:</p><p> </p><p><a href="https://www.engage.england.nhs.uk/consultation/proposed-contracting-arrangements-for-icps/" target="_blank">https://www.engage.england.nhs.uk/consultation/proposed-contracting-arrangements-for-icps/</a></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 10/04/2019 13:43:36 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4573 label Biography information for Dr Rosena Allin-Khan

1110984

	registered interest
	date	10/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Urinary Tract Infections: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 5 April 2019 to Question 237733, what representations he has received on the capability of NHS urinary trace infection screening tests to detect bacteria hidden in the bladder's lining.
	tabling member constituency	Tooting
	tabling member printed	Dr Rosena Allin-Khan
	uin	243537
	answer	answer is ministerial correction date of answer 17/04/2019 answer text <p>A search of the Department’s Ministerial correspondence database has identified four items of correspondence received on the capability of National Health Service urinary tract infection (UTI) screening tests to detect bacteria in the bladder's lining during the past 12 months. This figure represents correspondence received by the Department’s Ministerial correspondence unit only.</p><p>In November 2018 Public Health England published guidance on the diagnosis of UTIs. This guidance states that “no individual or combination (of symptoms or dipstick) are completely reliable in diagnosing UTI, thus severity of symptoms and safety-netting are important.”</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/04/2019 12:22:09 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4573 label Biography information for Dr Rosena Allin-Khan

1122543

	registered interest
	date	23/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Spinal Injuries
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effect of delays in discharges from NHS Spinal Cord Injury Centres on patients awaiting treatment; and what steps his Department has taken to reduce those delays.
	tabling member constituency	Tooting
	tabling member printed	Dr Rosena Allin-Khan
	uin	246564
	answer	answer is ministerial correction date of answer 01/05/2019 answer text <p>NHS England is aware of the benefits of timely admission to a Spinal Cord Injury Centre (SCIC). A key aim of the Spinal Cord Injury Review is to produce a service that is able to offer each newly injured patient prompt admission to a SCIC.</p><p>We are currently working with the existing eight centres to develop a network model that will allow the sharing of best practice and improve standardisation of high quality care. This would include learning from the experiences of centres that currently have the lowest waiting times for admission. The network would also enable the co-ordination of the actions of referring hospitals and their awareness of the referral processes to SCI centres and ensure they are supported with information and specialist advice about how best to look after cord injured patients prior to admission.</p><p>There is also work underway looking at options to increase SCI care provision to meet unmet demand across the eight centres, with the possibility of a new unit to serve the population that currently has limited access to a SCI centre. Any new SCI unit would need to be co-located with a major trauma centre.</p><p> </p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 01/05/2019 15:35:17 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4573 label Biography information for Dr Rosena Allin-Khan

1122698

	registered interest
	date	24/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Urinary Tract Infections: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 10 April 2019 to Question 243537, Urinary Tract Infections: Screening and with reference to the four items of correspondence cited in the Answer, what assessment he has made of the effectiveness of NHS UTI screening tests in detecting bacteria in the bladder's lining.
	tabling member constituency	Tooting
	tabling member printed	Dr Rosena Allin-Khan
	uin	247141
	answer	answer is ministerial correction date of answer 03/05/2019 answer text <p>In January 2019, the National Institute for Health and Care Excellence (NICE) published a revised Clinical Knowledge Summary ‘Urinary tract infection (lower) – women’. The Clinical Knowledge Summaries provide an overview of the process and evidence considered in developing the documents.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 03/05/2019 13:14:59 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4573 label Biography information for Dr Rosena Allin-Khan